The head of The Federal Trade Commission and a group of House lawmakers want Congress to add a provision in the healthcare plan that would prevent name-brand drug makers from paying generic makers to delay competition from cheaper generic alternatives.  This article from The New York Times.

Generics account for only about 22 percent of prescription drug spending in this country, although they represent nearly three-quarters of the prescriptions written, according to the research firm IMS Health. That means 78 percent of the nation’s drug bill goes toward the 25 percent of prescriptions written for name-brand medicines.

Click here for full article: